Biophagy’s Business Model
Biophagy is managing standard drug development programs in several therapeutic areas. It is also developing an OTC/DTC kit that will focus exclusively on autophagy stimulation and individual diagnostic measurement over an extended period.
|Proprietary Drug Discovery||CellWatch™|
Proprietary Drug Discovery
Biophagy’s proprietary drug discovery program has recently been granted a USPTO patent for a series of compounds that stimulate autophagy. These new drugs show promise in tuberculosis, SARS-CoV-2 (covid-19), and neurodegenerative disease. The company is currently investigating these indications and other potential avenues of development.
CellWatch™, Biophagy’s OTC product, is being rationally designed to stimulate autophagy for the individual health and longevity marketplace. The product kit will encompass a proprietary mix of rationally designed autophagy stimulants and include a method of measuring autophagy functioning in an individual.